about
The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?Atrial fibrillation in heart failure: what should we do?Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trialsThe past, present and future of renin-angiotensin aldosterone system inhibitionNovel pharmacological targets for the rhythm control management of atrial fibrillation.Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.Left Ventricular Filling Pressure as Assessed by the E/e' Ratio Is a Determinant of Atrial Fibrillation Recurrence after Cardioversion.2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situationsN-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials.Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertensionImpact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation: A meta-analysis and systematic review of randomized controlled trials.The role of the renin-angiotensin system blocking in the management of atrial fibrillation.Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.Systematic review and meta-analysis: renin-Angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope.Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications.Critical review of cancer risk associated with angiotensin receptor blocker therapy.The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease.The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation.Atrial fibrillation in heart failure.Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.A review of the epidemiological profile of patients with atrial fibrillation and heart failure.Individualized therapy in patients with atrial fibrillation: new look at atrial fibrillation.Atrial fibrillation in heart failure: drug therapies for rate and rhythm control.During ablation for atrial fibrillation, is simultaneous renal artery ablation appropriate?Novel therapeutic targets in the management of atrial fibrillation.Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials.The cost-effectiveness of irbesartan for hypertension.Blood pressure control versus atrial fibrillation management in stroke prevention.Device-Based Approaches to Modulate the Autonomic Nervous System and Cardiac Electrophysiology.A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome.Prerequisites for Exploring Predictors of Chronic Atrial Fibrillation Recurrence After AblationAssociation of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative.Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials.
P2860
Q26768696-2BA0D329-7C7B-4B1B-9EE1-AEF74D448E75Q26784426-673C75DF-90C7-4826-ABB0-DF800EA2418FQ26851803-8B8671CE-12EF-49C4-AF7E-C16FF66DFD0FQ28087109-62771B5A-CBF2-4EE6-B1A4-69E93A03F5C6Q34094354-AAE3A08B-CB34-4DDF-ACD9-69C17E31B230Q35489060-5F80A874-7296-4D2A-B3EE-9D7CCDDD9FA3Q36058755-F6AEDEF2-2C5A-4606-8C8A-8CFE2C6FF185Q36418761-69A2BB68-642A-45A1-8A72-86519DCFE409Q36572355-22AD8C41-F958-496F-BD00-DDD23BD71C7BQ36701732-A4174A7C-5A5B-48F1-BC37-E949C35BE9F7Q36824736-9DCF24DB-951E-4CE7-BD4D-B3EBFCE09E77Q36918956-7ABEE270-3E56-4432-8A1B-9CC809609E34Q37066818-2B6DB26C-81F5-4858-96C1-9D1229DCD2CBQ37078083-A1178D29-9B08-4389-8508-A94F1D8A375FQ37166906-8C6DDB3C-6340-434D-A9A4-3304C93832EEQ37225236-81EA3966-E36C-4506-902B-B015A6739DE4Q37496298-DEDA97CA-A8D9-4DDF-B36E-3F2F3E1FC1B5Q37691484-400F3C4F-ED9E-415B-A4C4-B6DDA4BE2FB9Q37868371-4439147D-01C0-4E97-B33C-AA400169CB0EQ37947093-AC7323F2-2E5A-4590-A6AB-7E516C66CA5CQ37963121-774A6A33-9BEC-4A72-AF60-031B7D9CC904Q37975493-14178376-146A-4A21-81A4-EB674443D18FQ38011656-E38280B2-344E-4C0A-96C7-6BE554533085Q38016454-A1399DDD-DFF3-42AC-A67C-D4F1DDC6AFBEQ38025390-8FC019AD-C18B-403E-A8AA-DF8887DECD0CQ38032181-A1EEDEF5-752B-44A5-9EF9-773B09887642Q38048843-A3D1E964-2302-4584-81E4-429F1D8F9A5DQ38055506-1E00ADE0-F6ED-4A92-AFB7-2720A00B91E6Q38056112-4323DBA7-1014-47E4-8DEC-121B75D036D8Q38108265-5826C77C-58C7-497F-AE10-59B34D3DFACBQ38128978-BADFCD39-DE11-45EA-A10B-C0DD466FF29AQ38236746-43DD1E80-7333-4390-A1D5-29B93B9118B0Q38267697-4FDB437A-FD11-4040-B1F7-E9D0D7E9D54EQ38363840-7AA000D2-634E-4881-AEC3-95DB22DC6723Q38429854-3EFCA02A-89E0-439A-AA0F-E7ACD60A94FEQ38719258-56EAFB73-576C-4053-B84E-E0957CBF15D5Q38770111-D5B7CD0B-95AF-4C72-BAEA-EF0160FF41E9Q38790555-4A8FA6B2-DE06-48EB-811F-AF3591DAB559Q38813385-3BCE4D36-AA4A-4348-A1BD-D014484EA9DDQ38826605-F074D5CC-8DD9-4A6D-B1C9-E98A5AF44679
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Irbesartan in patients with atrial fibrillation.
@en
Irbesartan in patients with atrial fibrillation.
@nl
type
label
Irbesartan in patients with atrial fibrillation.
@en
Irbesartan in patients with atrial fibrillation.
@nl
prefLabel
Irbesartan in patients with atrial fibrillation.
@en
Irbesartan in patients with atrial fibrillation.
@nl
P2093
P50
P356
P1476
Irbesartan in patients with atrial fibrillation.
@en
P2093
ACTIVE I Investigators
Campbell D Joyner
Jeff S Healey
Marc A Pfeffer
Marcus Flather
Robert G Hart
Stefan H Hohnloser
Stuart J Connolly
P304
P356
10.1056/NEJMOA1008816
P407
P577
2011-03-01T00:00:00Z